<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868163</url>
  </required_header>
  <id_info>
    <org_study_id>P19-454</org_study_id>
    <nct_id>NCT03868163</nct_id>
  </id_info>
  <brief_title>Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation</brief_title>
  <acronym>EVEREST</acronym>
  <official_title>Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to assess the effectiveness of Glecaprevir plus Pibrentasvir in participants
      with chronic hepatitis C in a real-life setting across clinical practice populations in the
      Russian Federation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">August 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>SVR12 defined as the hepatitis C virus (HCV) ribonucleic acid (RNA) level less than the lower limit of quantification/detection (&lt;LLOQ/D) 12 weeks after the last dose of Glecaprevir plus Pibrentasvir (GLE/PIB).with a sensitive polymerase chain reaction [PCR] test with an LLoQ/D of &lt;50 IU/mL or as described in a validated assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR12 by Mono HCV or co-infected HCV/HIV Status</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>SVR12 defined as the HCV RNA level &lt;LLOQ/D 12 weeks after the last dose of GLE/PIB.with a sensitive PCR test with an LLoQ/D of &lt;50 IU/mL or as described in a validated assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR12 by CHC Genotype</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>SVR12 defined as the HCV RNA level &lt;LLOQ/D 12 weeks after the last dose of GLE/PIB.with a sensitive PCR test with an LLoQ/D of &lt;50 IU/mL or as described in a validated assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR12 by Cirrhosis Status</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>SVR12 defined as the HCV RNA level &lt;LLOQ/D 12 weeks after the last dose of GLE/PIB with a sensitive PCR test with an LLoQ/D of &lt;50 IU/mL or as described in a validated assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR12 by Previous Treatment Experience</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>SVR12 defined as the HCV RNA level &lt;LLOQ/D 12 weeks after the last dose of GLE/PIB with a sensitive PCR test with an LLoQ/D of &lt;50 IU/mL or as described in a validated assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SVR12 by Patients Who Use Drugs</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>SVR12 defined as the HCV RNA level &lt;LLOQ/D 12 weeks after the last dose of GLE/PIB with a sensitive PCR test with an LLoQ/D of &lt;50 IU/mL or as described in a validated assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Elderly Participants Achieving SVR12</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>SVR12 defined as the HCV RNA level &lt;LLOQ/D 12 weeks after the last dose of GLE/PIB with a sensitive PCR test with an LLoQ/D of &lt;50 IU/mL or as described in a validated assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Commodities</measure>
    <time_frame>Up to approximately 16 weeks</time_frame>
    <description>Percentage of Patients with Commodities from the decision to initiate treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Taking Concomitant Medications</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>The percentage of participants taking concomitant medications from the decision to initiate treatment through up to 12 weeks after the last dose of GLE/PBR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of GLE/PIB Dose Taken</measure>
    <time_frame>Up to approximately 16 weeks</time_frame>
    <description>Percentage of GLE/PIB dose taken by patient report in relation to the prescribed target dose (that is, the number of pills taken out of the number that should have been taken).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Health Care Resource Utilization (HCRU)</measure>
    <time_frame>Up to approximately 28 weeks</time_frame>
    <description>Health Care Resource Utilization (HCRU) for a patient will be the total number of visits/touchpoints (face to face or phone call) with a Health Care Provider (HCP) or designee in relation to their HCV infection during the study.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">161</enrollment>
  <condition>Chronic Hepatitis C (CHC)</condition>
  <arm_group>
    <arm_group_label>Glecaprevir plus Pibrentasvir</arm_group_label>
    <description>Participants in this observational study will receive treatment with glecaprevir and pibrentasvir for up to 16 weeks for treatment of chronic hepatis C (CHC) genotypes 1, 2, 3, 4, 5, or 6.
The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice, international guidelines and/or label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CHC in a real world clinical practice setting.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-na√Øve or - pegIFN (or IFN), and/or Ribavirin (RBV) and/or sofosbuvir (PRS)
             experienced with confirmed CHC, genotypes 1, 2, 3, 4, 5, or 6, with or without
             compensated cirrhosis, receiving combination therapy with the all oral GLE/PIB regimen
             according to standard of care, international guidelines and in line with the current
             local label.

          -  May be enrolled up to 4 weeks after treatment initiation.

          -  Patients must voluntarily sign and date Informed Consent Form prior to inclusion into
             the study,

          -  Patient must not be participating or intending to participate in a concurrent
             interventional therapeutic trial.

        Exclusion Criteria:

          -  None.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LLC Medical Company Hepatolog /ID# 212384</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast</state>
        <zip>443063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor Pasechnikov Gastroenterology and Pankreatology clinic /ID# 217035</name>
      <address>
        <city>Stavropol</city>
        <state>Stavropol Skiy Kray</state>
        <zip>355035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. F. Agafonov Republican Clin /ID# 212381</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Ural State Medical univ /ID# 212020</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454052</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Inf. Dis Hospital 1 /ID# 217033</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIH Orlovskiy region city hospital named after S.P. Botkin /ID# 212383</name>
      <address>
        <city>Oryol</city>
        <zip>302038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm Regional Center of Cepato /ID# 213992</name>
      <address>
        <city>Perm</city>
        <zip>614000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara State Medical Universit /ID# 217029</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg AIDS Center /ID# 212380</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>glecaprevir</keyword>
  <keyword>pibrentasvir</keyword>
  <keyword>real world setting</keyword>
  <keyword>Observational Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

